

- Amendments to the Claims -

Amend claims 3, 6 and 9 and cancel claims 4, 5, 7 and 10 - 13 as follows:

1. (Original) A combination of (a) a histamine H₁ receptor antagonist and (b) an antagonist that is at least 10-fold selective for the histamine H₄ receptor as compared to the histamine H₃ receptor.

2. (Canceled)

Ar 3. (Currently amended) A combination of claim 1 (a) a histamine H₁ receptor antagonist and (b) an antagonist that is at least 10-fold selective for the histamine H₄ receptor as compared to the histamine H₃ receptor, for administration simultaneously, separately or sequentially, for use as a medicament for the treatment of a disease or disorder that may be treated by antagonism of either or both of the histamine H₁ and H₄ receptors such as allergic rhinitis or asthma.

4. (Canceled)

5. (Canceled)

Cl 6. (Currently amended) A pharmaceutical composition comprising a combination of claim 1 including (a) a histamine H₁ receptor antagonist and (b) an antagonist that is at least 10-fold selective for the histamine H₄ receptor as compared to the histamine H₃ receptor, and a pharmaceutically acceptable excipient, diluent or carrier.

7. (Canceled)

8. (Original) An antagonist that is at least 10-fold selective for the histamine H₄ receptor as compared to the histamine H₃ receptor.

Cl 9. (Currently amended) A pharmaceutical composition comprising including an antagonist as claimed in claim 8 and a pharmaceutically acceptable excipient, diluent or carrier.

10. - 13. (Canceled)